[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Ezzat AA, Ibrahim EM, El Weshi AN, Khafaga YM, AlJurf M, Martin JM, Ajarim DS, Bazarbashi SN, Stuart RK, Zucca E: Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. Head Neck; 2001 Jul;23(7):547-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients.
  • BACKGROUND: Waldeyer's ring (WR) is the primary site of non-Hodgkin's lymphoma (NHL) involvement in approximately 5% to 10% of all lymphoma patients, and it accounts for more than half of all primary extranodal lymphomas of the head and neck.
  • Seventy five (58%), 46 (35%), and 9 (7%) patients had primary tonsillar, nasopharyngeal, and base of the tongue lymphoma, respectively.
  • Chemotherapy (CT) was given to 58 (45%) patients, whereas 26 (20%) received radiation therapy (RTX), and 46 (35%) were managed with a combination of chemotherapy and radiotherapy (CMT).
  • One hundred nine (84%), 16 (12%), and 5 (4%) patients attained complete remission (CR), partial remission (PR), and treatment failure, respectively, with no difference in CR rates between the three therapeutic modalities.
  • Of those patients with DLC, 90 (83%), 15 (14%), and 4 (3%) demonstrated CR, PR, and treatment failure, respectively.
  • Cox proportional hazards model identified primary tonsillar site and a low-risk group as defined by the modified IPI were associated with favorable OS.
  • The median event-free survival was 82.3 months, with the primary tonsillar site, and low-risk modified IPI group were associated with favorable EFS in a multivariate analysis.
  • The CMT was not associated with a superior OS compared with either of the single modality treatments; however, it was associated with more favorable EFS.
  • Primary tonsillar site and the low-risk group of the modified IPI predicted favorable OS and EFS.
  • CMT is probably superior to single modality treatment; however, prospective studies are warranted.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 John Wiley & Sons, Inc.
  • (PMID = 11400243.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Pellier I, N'Golet L, Rachieru P, Rousselet MC, Geneviève F, Moles MP, Hermine O, Rialland X: Disseminated nasal-type natural killer/T-cell lymphoma in a child: a case report. J Pediatr Hematol Oncol; 2009 May;31(5):362-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated nasal-type natural killer/T-cell lymphoma in a child: a case report.
  • The authors report a case of nasal-type natural killer/T (NK/T)-cell lymphoma in a 15 years old girl, with rapid fatal evolution.
  • NK/T proliferations are very rare and only a few cases have been described in children, most of them NK/T-cell lymphoma or leukemia, but not nasal-type NK/T-cell lymphoma.
  • Clinical and biologic characteristics of these diseases are discussed with focus on their aggressivity and poor response to conventional chemotherapy.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Drug Resistance, Neoplasm. Fatal Outcome. Female. Humans. Tonsillar Neoplasms / drug therapy. Tonsillar Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415021.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Yong W, Zhang Y, Zheng W, Wei Y: Prognostic factors and therapeutic efficacy of combined radio-chemotherapy in Waldeyer's ring non-Hodgkin lymphoma. Chin Med J (Engl); 2000 Feb;113(2):148-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and therapeutic efficacy of combined radio-chemotherapy in Waldeyer's ring non-Hodgkin lymphoma.
  • OBJECTIVE: To improve the prognosis and therapeutic efficacy of Waldeyer's ring non-Hodgkin lymphoma (NHL-WR), combined radio-chemotherapy was used to treat the patients with NHL-WR and prognostic factors were analyzed.
  • METHODS: Ninety patients with stage I-IV NHL-WR were treated with combined radio-chemotherapy.
  • The combination chemotherapy consisted of COPP (cyclophosphamide [CTX], vincristine [VCR], procarbazine [PCZ], prednisone [PDN]) or CHOP (CTX, ADM, VCR and PDN).
  • CONCLUSIONS: Combined radio-chemotherapy can improve the 5-year survival rate for the patients with NHL-WR, especially for stage I, II patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Tonsillar Neoplasms / drug therapy. Tonsillar Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Survival Rate. Treatment Outcome


Advertisement
4. Yamazaki R, Takayama N, Hamano Y, Mori T, Okamoto S, Ikeda Y: [Localized recurrence of acute lymphoblastic leukemia-L3 in the tonsil after 3-years' remission]. Rinsho Ketsueki; 2002 Nov;43(11):1004-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Localized recurrence of acute lymphoblastic leukemia-L3 in the tonsil after 3-years' remission].
  • Recurrence of Burkitt's lymphoma (BL)/acute lymphoblastic leukemia (ALL)-L3 after a long-term remission is very rare.
  • We herein report on a case of BL/ALL-L3 indicating solitary recurrence in the tonsil after a 3-year remission.
  • A 50-year-old man was diagnosed as having Burkitt's type ALL-L3 with involvement of the stomach and abdominal lymph nodes.
  • He was treated with intensive chemotherapy consisting of methotrexate and cyclophosphamide (ALL-BFM86 protocol), and a complete remission was achieved.
  • After sustaining the remission for three years, a swelling of the right tonsil was observed, which was histologically diagnosed as Burkitt's lymphoma.
  • The pattern of c-myc rearrangement of the tonsil demonstrated by southern blotting was identical to that of the bone marrow at initial presentation and the recurrence of primary ALL-L3/BL was thus confirmed.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Tonsillar Neoplasms / etiology
  • [MeSH-minor] Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Recurrence. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12508487.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Ree HJ, Kikuchi M, Lee SS, Ohshima K, Yang WI, Ko YH, Cho EY, Rhee JC: Focal follicular features in tonsillar diffuse large B-cell lymphomas: follicular lymphoma with diffuse areas or follicular colonization. Hum Pathol; 2002 Jul;33(7):732-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal follicular features in tonsillar diffuse large B-cell lymphomas: follicular lymphoma with diffuse areas or follicular colonization.
  • Focal follicular features in diffuse large B-cell lymphomas (DLBCLs) are bound to raise the question of follicular lymphoma (FL) with diffuse areas, because the diagnosis of FL is based on the presence of follicular areas, even though focal.
  • We report 7 cases of primary tonsillar DLBCLs with focal follicular features that presented with morphologic, immunohistochemical, and biological features distinct from those of FL.
  • Five of 7 patients were younger than 60, the median age of other patients with primary tonsillar DLBCL.
  • After chemotherapy or radiotherapy, complete remission was achieved with ease in all patients, but 2 patients who were treated with chemotherapy alone relapsed at 24 and 30 months.
  • In conclusion, tonsillar DLBCL includes a small (10%) but distinct subgroup that warrants distinction from FL with predominant diffuse areas or de novo DLBCL.
  • It appears that the focal follicular features in tonsillar DLBCL likely represent follicular colonization of marginal zone B-cell lymphoma, probably high-grade, if the possibility of FL is excluded.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Palatine Tonsil / pathology. Tonsillar Neoplasms / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12196925.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


6. Souabni L, Elleuch M, Amira C, Sellami S: Malignant lymphoma of the tonsil in a patient with Behçet's disease. Joint Bone Spine; 2008 Oct;75(5):616-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the tonsil in a patient with Behçet's disease.
  • Several connective tissue diseases such as rheumatoid arthritis and polymyositis are associated with cancer.
  • We report a case of lymphoma during the course of Behçet disease.
  • A 46-year-old man with a 14-year history of Behçet disease was diagnosed with non-Hodgkin malignant lymphoma of the right tonsil.
  • He met international criteria for Behçet disease, which manifested as refractory oral ulcers requiring dapsone treatment.
  • He achieved a complete remission of the lymphoma after three chemotherapy courses and local radiation therapy (45 Gy).
  • [MeSH-major] Behcet Syndrome / pathology. Lymphoma, Non-Hodgkin / pathology. Tonsillar Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Remission Induction


7. Gao YH, Li YX, Zhao LJ, Yuan ZY, Liu XF, Yu ZH: [Treatment of early stage primary tonsil non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2003 Apr;24(4):190-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of early stage primary tonsil non-Hodgkin's lymphoma].
  • OBJECTIVE: To investigate the treatment for patients with early stage primary tonsil non-Hodgkin's lymphoma (NHL).
  • METHODS: Two hundred and thirteen patients with previously untreated early stage primary tonsil NHL were reviewed.
  • The primary treatment for stage I was radiotherapy alone in 12 and combined modality therapy (CMT) in 23 patients.
  • The primary treatment for stage II was radiotherapy alone in 57,chemotherapy alone in 2, and CMT in 119 patients.
  • RESULTS: The 5-year overall survival, cancer specific survival (CSS) AND disease-free survival (DFS) for the early stage primary tonsil non-Hodgkin's lymphoma were 65%, 70% and 61%, respectively.
  • There was no significant difference of efficacy between the two treatment s for the patients with stage I disease.
  • CONCLUSION: Patients with stage I tonsil non-Hodgkin's lymphoma treated with radiotherapy alone or CMT can achieve an excellent outcome.
  • It was suggested that CMT should be used for the patients with early stage primary tonsil non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12864949.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Singh SK, Gupta AK, Jha V, Kohli HS, Gupta KL, Minz M, Sakhuja V: Treatment of oropharyngeal cancer in renal transplant recipients without cessation of immunosuppressive therapy. Transplant Proc; 2006 Sep;38(7):2088-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of oropharyngeal cancer in renal transplant recipients without cessation of immunosuppressive therapy.
  • Reduction or cessation of immunosuppressive therapy has been advocated in these cases to prevent tumor progression and recurrence.
  • We evaluated the outcome of treatment of oropharyngeal cancer (OC) after renal transplantation without cessation of immunosuppressive therapy.
  • METHODS: The database of patients with OC after renal transplantation was analyzed with respect to age, sex, type of immunosuppression, interval between transplantation and diagnosis of cancer, as well as method of treatment and survival.
  • RESULTS: Thirty one (2.06%) renal transplant recipients developed malignancy including 6 (20%) with OC.
  • Lingual cancer was seen in three, and one each showed an isolated tonsillar lymphoma, a parotid carcinoma, or a carcinoma of the larynx with only the last having had two other malignancies in the past.
  • Average time from transplantation to diagnosis of OC was 106 months.
  • The interval was the shortest (2 years) for tonsillar lymphoma in an 18-year-old patient who received cyclosporine and showed features of left follicular tonsillitis.
  • The patient with advanced carcinoma of the larynx did not receive any treatment and succumbed within 3 months.
  • The dose of cyclosporine was reduced in the lymphoma case but immunosuppression was not altered in the other patients.
  • CONCLUSION: Comprehensive treatment of OC after renal transplantation without withdrawing the immunosuppression prolonged the life of these patients with functioning grafts.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Kidney Transplantation / immunology. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980008.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


9. Sato Y, Onishi N, Morito T, Takata K, Mizobuchi K, Nagatsuka H, Ichimura K, Tanaka T, Tamura M, Yoshino T: Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype. Cancer Sci; 2009 Jan;100(1):42-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype.
  • Although tonsillar lymphomas have been rather well characterized, lymphomas originating from non-tonsillar regions, such as the gingiva, palate, and tongue, have not been well studied.
  • We examined the pathology of clinical samples obtained from 21 patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma.
  • Immunohistological examination of CD10, Bcl-6, and MUM1 determined that 17 of 21 (81%) samples exhibited non-germinal center B-cell type, an increased proportion of non-germinal center B-cell type compared with previous reports in samples of tonsillar origin (P<0.05).
  • The four remaining samples exhibited germinal center B-cell type, although one sample expressed MUM1.
  • Extranodal diffuse large B-cell lymphomas of non-germinal center B-cell type are generally characterized by poor prognosis, regardless of localized disease.
  • Interestingly, our results indicate that, unlike similar lymphomas of tonsillar origin, localized primary non-tonsillar oral diffuse large B-cell lymphomas exhibit favorable prognosis, suggesting that these lymphomas may be clinicopathologically distinct.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / mortality. Mouth Neoplasms / mortality

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018759.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Tsujioka T, Wada H, Suemori S, Sadahira Y, Sugihara T: [CD56-positive peripheral T-cell lymphoma primarily presenting with tonsillar swelling]. Rinsho Ketsueki; 2004 Oct;45(10):1119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD56-positive peripheral T-cell lymphoma primarily presenting with tonsillar swelling].
  • A 51-year-old woman was admitted to our hospital with tonsillar swelling.
  • After tonsillectomy was performed, she was diagnosed as having CD56-positive T-cell lymphoma, mainly composed of small and medium-sized atypical cells.
  • We provided MCEC therapy followed by autologous peripheral blood stem cell transplantation, and complete remission (CR) was achieved.
  • It is rare for CD56-positive T-cell lymphoma to occur primarily in the tonsils.
  • Because small bowel ulcers were revealed during the course of induction chemotherapy, we report a valuable case in which suspected CD56-positive enteropathy-type T-cell lymphoma (ETL) occurred primarily in the tonsils.
  • [MeSH-major] Ileal Neoplasms. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / therapy. Neoplasms, Second Primary. Tonsillar Neoplasms / diagnosis. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Antigens, CD56 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Middle Aged. Neoplasm Staging. Nitrosourea Compounds / administration & dosage. Peripheral Blood Stem Cell Transplantation. Remission Induction. Transplantation, Autologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553048.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Nitrosourea Compounds; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; RYH2T97J77 / ranimustine
  •  go-up   go-down


11. Wang CP, Hsieh CY, Chang YL, Lou PJ, Yang TL, Ting LL, Ko JY: Postirradiated neuroendocrine carcinoma of the sinonasal tract. Laryngoscope; 2008 May;118(5):804-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this present study, we report our treatment experience with sinonasal NEC.
  • RESULTS: Ten tumors were primary NEC without previous radiation, and eight tumors were postirradiated NEC occurring within the radiation field for previous nasopharyngeal carcinoma in six patients and tonsillar lymphoma in one and neck metastasis of unknown primary origin in one, with an interval between previous radiotherapy and diagnosis of NEC from 82 to 385 months, with a mean of 197 months.
  • Three patients received induction chemotherapy or primary radiotherapy with further definitive treatment.
  • In comparing primary NEC with postirradiated NEC, they were similar in age, sex distribution, stage, pathology, and treatment, and the 5-year overall survival rates were 70% and 62.5%, respectively.
  • The prognoses of postirradiated NEC and primary NEC appear to be similar despite the relatively short follow-up period in the postirradiated NEC group.
  • [MeSH-minor] Adult. Aged. Carcinoma, Small Cell / radiotherapy. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Combined Modality Therapy. Female. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / surgery. Humans. Lymphoma / pathology. Lymphoma / radiotherapy. Male. Maxillary Neoplasms / secondary. Maxillary Neoplasms / surgery. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Radiotherapy Dosage. Retrospective Studies. Tonsillar Neoplasms / pathology. Tonsillar Neoplasms / radiotherapy. Tonsillar Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520182.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Qi J, Fan X, Wang C, Ma J, Tang H: [Unilateral tonsillar enlargement and malignant tonsillar lymphoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Sep;16(9):469-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unilateral tonsillar enlargement and malignant tonsillar lymphoma].
  • OBJECTIVE: To study clinic characters of malignant lymphoma in patients with unilateral tonsillar enlargement for early discover and synthetic therapy clinic characters of malignant lymphoma patients with unilateral tonsillar enlargement for early discover and synthetic therapy.
  • METHOD: 10 cases of non-Hodgkin's lymphoma (NHL) out of 100 unilateral tonsillar enlargement patients given tonsillectomy were treated with combined chemotherapy.
  • CONCLUSION: Progressing unilateral swollen tonsil found in a short time with suspicious appearance should be given tonsillectomy for histopathology; upper airway and systematic symptoms such as fever and rigors, night sweats; lymphatic enlargement in cervical, axillary, inguinal region; hepatosplenomegaly should be thought of main traits of malignant lymphoma, and hyposensitivity to medicine should be taken malignant lymphoma into account.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Tonsillectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15515534.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Manganini M, Serafini M, Bambacioni F, Casati C, Erba E, Follenzi A, Naldini L, Bernasconi S, Gaipa G, Rambaldi A, Biondi A, Golay J, Introna M: A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. Hum Gene Ther; 2002 Oct 10;13(15):1793-807
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors.
  • We have investigated the capacity of two human immunodeficiency virus type 1-derived lentivectors, differing in the presence of a 118-bp pol fragment containing the cPPT/CTS element, to transduce human normal primary cells of different hematopoietic lineages.
  • Still higher transduction of T lymphocytes can be achieved after stimulation with phytohemagglutinin and interleukin 2 (up to 78% with the cPPT vector vs. 42% with the no-cPPT vector).
  • Finally, both viruses do not transduce either resting or proliferating tonsillar B lymphocytes.
  • [MeSH-minor] B-Lymphocytes / drug effects. B-Lymphocytes / virology. Cell Division / drug effects. Fibroblasts. Genes, Reporter. Green Fluorescent Proteins. Humans. Interleukin-15 / pharmacology. Interleukin-2 / pharmacology. Kidney. Luminescent Proteins / analysis. Luminescent Proteins / genetics. Lymphoma, Follicular / pathology. Moloney murine leukemia virus / genetics. Phytohemagglutinins / pharmacology. Terminal Repeat Sequences. Tumor Cells, Cultured

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12396613.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-15; 0 / Interleukin-2; 0 / Luminescent Proteins; 0 / Phytohemagglutinins; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


14. Hussain BM, Geetha N, Lali V, Pandey M: Rituximab induced hypoglycemia in non-Hodgkin's lymphoma. World J Surg Oncol; 2006;4:89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab induced hypoglycemia in non-Hodgkin's lymphoma.
  • CASE PRESENTATION: A 50 year old female presented with a left tonsillar non Hodgkin's lymphoma and was started on R-CHOP chemotherapy.
  • Twenty four hours after the first rituximab infusion, she developed hypoglycemia which was managed by IV glucose infusion.
  • Possibilities of hypoglycemia should be kept in mind in patients developing symptoms like fatigue, restlessness, and sweating while on rituximab therapy.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):310-1 [14724317.001]
  • (PMID = 17156470.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1764014
  •  go-up   go-down


15. Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G, Bezombes C: Syk-dependent mTOR activation in follicular lymphoma cells. Blood; 2006 Dec 15;108(13):4156-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Syk-dependent mTOR activation in follicular lymphoma cells.
  • The mammalian target of rapamycin (mTOR) is emerging as a promising target for antitumor therapy.
  • This study shows that in follicular lymphoma (FL) cells, mTOR is active because the cells displayed rapamycin-sensitive phosphorylation of p70S6 kinase and 4E-BP1.
  • Moreover, immunohistochemistry applied on lymph node tissue sections obtained from patients with FL revealed that, in most cases, p70S6 kinase was highly phosphorylated compared to normal tonsillar tissue.
  • Finally, Syk inhibition by piceatannol or by siRNA plasmids resulted in a potent inhibition of mTOR activity in FL cells, as well as in mantle cell lymphoma, Burkitt lymphoma, and diffuse large B-cell lymphoma.
  • These findings suggest that the Syk-mTOR pathway has a critical function in FL survival, and therefore, that Syk could be a promising new target for B-lymphoma therapy.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / metabolism. Lymphoma, Follicular / enzymology. Neoplasm Proteins / metabolism. Protein Kinases / metabolism. Protein-Tyrosine Kinases / metabolism. Signal Transduction
  • [MeSH-minor] Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / enzymology. Burkitt Lymphoma / pathology. Cell Line, Tumor. Enzyme Activation / drug effects. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / pathology. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / enzymology. Lymphoma, Mantle-Cell / pathology. Palatine Tonsil / enzymology. Palatine Tonsil / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Phospholipase D / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / pharmacology. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Stilbenes / pharmacology. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912221.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Stilbenes; 4339-71-3 / 3,3',4,5'-tetrahydroxystilbene; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 3.1.4.4 / Phospholipase D
  •  go-up   go-down


16. Qin Y, Shi YK, He XH, Yang JL, Yang S, Yu YX, Li B, Wang QL, Zhou LQ, Sun Y: [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Ai Zheng; 2006 Apr;25(4):481-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
  • BACKGROUND & OBJECTIVE: Head and neck lymphoma develops predominantly in the tonsil.
  • This study was to investigate the clinical features of primary non-Hodgkin's lymphoma (NHL) of the tonsil, and to explore possible ways to improve the prognosis and quality of life of the patients after treatment.
  • METHODS: Clinical data of 89 naive patients with NHL of the tonsil, treated from May 1990 to Jan.
  • Stage I-II patients received radiochemotherapy-predominant treatment, whereas stage III-IV patients received chemotherapy-predominant treatment.
  • RESULTS: Of the 89 cases, 60 (67%) were diffuse large B-cell subtype, 11 (12%) were peripheral T-cell subtype, 5 (6%) were indolent lymphoma, 1 was anaplastic large T-cell lymphoma, and 1 was T lymphoblastic lymphoma; 81 (91%) were stage I-II disease.
  • Of the 89 patients, 58 (72%) received radiochemotherapy, 19 (21%) received radiotherapy alone, 3 received chemotherapy alone, and 1 received radiochemotherapy combined with rituximab.
  • Cox regression multivariate analysis showed that the survival rate was correlated to the value of international prognostic index (IPI), and whether the patient had primary refractory or relapsed disease, but was not correlated to sex, age, pathologic subtype, B symptoms, and bulky disease.
  • CONCLUSIONS: Most patients with NHL of the tonsil are at early stages, with good prognosis.
  • Diffuse large B-cell lymphoma is the most common pathologic subtype.
  • Primary refractory, relapse, and IPI>1 are independent prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Tonsillar Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613685.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


17. Gurkaynak M, Cengiz M, Akyurek S, Ozyar E, Atahan IL, Tekuzman G: Waldeyer's ring lymphomas: treatment results and prognostic factors. Am J Clin Oncol; 2003 Oct;26(5):437-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Waldeyer's ring lymphomas: treatment results and prognostic factors.
  • Optimal management of patients with localized Waldeyer's ring (WR) lymphoma remains controversial due to the lack of randomized studies and heterogenous grouping of most reported series.
  • In this retrospective study, we have evaluated the possible prognostic factors and treatment outcome of WR non-Hodgkin's lymphoma.
  • Between December 1993 and February 2000, 32 patients with WR lymphoma, stage I (11 patients) and stage II (21 patients) were treated.
  • Combined chemotherapy and radiotherapy was the primary modality of therapy for intermediate or high-grade lymphoma.
  • Chemotherapy was median 6 courses of CHOP (cyclophosphamide, doxorubicin (Adriamycin), vincristine, and prednisolone) in 26 patients and CEOP (cyclophosphamide, doxorubicin, etoposide, and prednisone).
  • Radiotherapy volume was involved field and the median dose was 40 Gy.
  • Two patients developed recurrence, both salvaged with further chemotherapy.
  • Our results suggest that combined chemotherapy and involved field radiotherapy is appropriate treatment for stage I-II WR lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Nasopharyngeal Neoplasms / mortality. Tongue Neoplasms / mortality. Tonsillar Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14528067.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ueda T, Tsutani H: [Primary extranodal malignant lymphoma]. Nihon Rinsho; 2000 Mar;58(3):673-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary extranodal malignant lymphoma].
  • Primary extranodal lymphoma with high frequency and/or unique feature in Japan is discussed.
  • Waldeyer ring lymphoma is most frequent(30%).
  • Most tumors consist of diffuse, large cell type of B cell.
  • Gastrointestinal lymphoma is another frequent lymphoma.
  • Surgical rejection followed by chemotherapy and radiation therapy achieved high response.
  • Pyothorax-associated lymphoma is a unique entity reported in Japan.
  • In intravascular lymphomas, lymphoma cells regionally exist in small vessel and are diffuse, large cell type of B cells.
  • Bone lymphoma is found in 4-8%.
  • [MeSH-major] Gastrointestinal Neoplasms. Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Tonsillar Neoplasms
  • [MeSH-minor] Bone Neoplasms / therapy. Combined Modality Therapy. Empyema, Pleural / complications. Humans. Prognosis. Survival Rate. Vascular Neoplasms / therapy

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741145.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 12
  •  go-up   go-down


19. Chang DT, Mendenhall NP, Lynch JW, Morris CG, Olivier KR: Long-term outcomes for stage I-II aggressive non-Hodgkin lymphoma of Waldeyer's ring. Am J Clin Oncol; 2009 Jun;32(3):233-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes for stage I-II aggressive non-Hodgkin lymphoma of Waldeyer's ring.
  • PURPOSE: To determine the long-term outcome of patients treated at the University of Florida for aggressive non-Hodgkin lymphoma (NHL) of Waldeyer's ring.
  • Of this group, 20 patients were treated with RT alone and 26 with combined-modality therapy (CMT) with the addition of chemotherapy: 24 patients with induction and 2 with concurrent or adjuvant chemotherapy.
  • CONCLUSIONS: Similar to other sites, out-of-field recurrences are the primary pattern of failure for NHL of Waldeyer's ring.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Tonsillar Neoplasms / drug therapy. Tonsillar Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433961.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Laskar S, Bahl G, Muckaden MA, Nair R, Gupta S, Bakshi A, Gujral S, Shet T, Shrivastava SK, Dinshaw KA: Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required? Cancer; 2007 Aug 15;110(4):816-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?
  • BACKGROUND: The purpose was to evaluate the prognostic factors and treatment outcome of Indian patients with primary diffuse large B-cell lymphoma (DLBCL) of the tonsil treated at a single institution.
  • METHODS: In all, 121 patients with DLBCL of the tonsil, treated at the Tata Memorial Hospital, Mumbai, India, from January 1990 to December 2002, were included.
  • Treatment consisted of a combination of chemotherapy (CTh) and radiotherapy (RT) for the majority of patients (69.4%).
  • Among those receiving RT, 64% received an RT dose of > or =45 Gy.
  • The complete response (P = .053), DFS (P = .039), and OS (P = .014) rates were significantly better for patients receiving an RT dose > or =45 Gy.
  • A combined modality treatment, consisting of CTh and RT (with an RT dose of > or =45 Gy), results in a satisfactory outcome in patients with this uncommon neoplasm.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. India. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582622.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Gao Y, Li Y, Yuan Z, Zhao L, Liu X, Gu D, Qian T, Yu Z: [Prognostic factors in patients with primary non-Hodgkin's lymphoma of the tonsil]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):483-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in patients with primary non-Hodgkin's lymphoma of the tonsil].
  • OBJECTIVE: To investigate the prognostic value of the size of primary tumor (T staging) and international prognostic index (IPI) for patients with non-Hodgkin's lymphoma (NHL) of the tonsil, and to recommend the treatment strategy for early stage patients.
  • METHODS: 306 patients with untreated NHL of the tonsil were reviewed.
  • Twelve stage I patients were given radiotherapy alone and 23 stage II patients were given combined modality therapy (CMT).
  • For patients with stage II lesion, 57 were given radiotherapy alone, 2 chemotherapy alone and 119 CMT.
  • Chemotherapy was the main treatment in patients with stage III or IV lesions.
  • RESULTS: The 5-year cancer specific survival (CSS) was 74% for patients with T(1), 59% for T(2), 56% for T(3) and 26% for T(4), respectively (P = 0.000).
  • CONCLUSION: The T staging of the primary tumor and IPI are the important prognostic factors of patients with NHL of the tonsil.
  • Combined modality therapy significantly improves the disease free survival of stage II patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Tonsillar Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485504.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, Lee JS, Kim MJ, Jung WY, Kim HK, Yeom BW, Kim IS, Kim JS: NK/T-cell lymphoma associated with Epstein-Barr virus in a patient infected with human immunodeficiency virus: an autopsy case. Int J Hematol; 2004 Jun;79(5):480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK/T-cell lymphoma associated with Epstein-Barr virus in a patient infected with human immunodeficiency virus: an autopsy case.
  • Natural killer (NK)/T-cell lymphoma associated with Epstein-Barr virus (EBV) in a patient infected with human immunodeficiency virus (HIV) is very rare.
  • The authors encountered a case of NK/T-cell lymphoma in a 36-year-old man who presented with an ulcerative mass on both tonsils.
  • On immunohistochemical staining, the infiltrated lymphoid cells of the tonsils demonstrated positvity for CD3, CD56, UCHL1, and granzyme, a finding compatible with NK/T-cell lymphoma.
  • The patient received radiation therapy and chemotherapy, but died as a result of opportunistic infection of invasive aspergillosis after tumor recurrence.
  • To our knowledge, this is the first case in an HIV patient of NK/T-cell lymphoma of the tonsils associated with EBV, confirmed by autopsy.
  • NK/T-cell lymphoma should be considered in the HIV-positive patients with an ulcerating tonsillar mass.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. HIV Infections / complications. Killer Cells, Natural / immunology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / virology. Tonsillar Neoplasms / immunology. Tonsillar Neoplasms / virology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Aspergillosis and HIV .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Intern Med. 2002 May;13(3):170-179 [12020624.001]
  • [Cites] Lab Invest. 1983 Sep;49(3):371-7 [6193334.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):909-16 [8101471.001]
  • [Cites] Leuk Lymphoma. 1999 May;33(5-6):451-8 [10342573.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1989 Mar-Apr;83(2):259 [2609381.001]
  • [Cites] Jpn J Cancer Res. 1989 Feb;80(2):99-101 [2542204.001]
  • [Cites] Arch Pathol Lab Med. 2001 May;125(5):660-2 [11300939.001]
  • [Cites] N Engl J Med. 1988 Mar 24;318(12):733-41 [2831453.001]
  • [Cites] Cancer. 1990 Dec 1;66(11):2407-13 [2245397.001]
  • [Cites] Am J Pathol. 1991 Jan;138(1):149-63 [1846263.001]
  • [Cites] J Clin Pathol. 1986 Apr;39(4):399-405 [2422219.001]
  • [Cites] Pathol Res Pract. 2002;198(5):327-32 [12092768.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):738-41 [12033970.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3350-6 [8389615.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Mar;41(3):299-315 [11880206.001]
  • (PMID = 15239400.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


24. Mele L, Pagano L, Equitani F, Chiusolo P, Rossi E, Zini G, Teofili L, Leone G: Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkin's lymphoma A case report and review of literature. Haematologica; 2000 May;85(5):544-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkin's lymphoma A case report and review of literature.
  • In this paper we describe a case of a 65-year old man with a lymphoid blastic crisis of a chronic granulocytic leukemia occurring seven years after a palatine tonsillar non-Hodgkin's lymphoma treated with chemotherapy and radiation therapy.
  • The patient died within a few months, unresponsive to any treatment.
  • [MeSH-minor] Aged. Bone Marrow Cells / pathology. Cytogenetics. Fatal Outcome. Fusion Proteins, bcr-abl / genetics. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Male. Neoplasms, Second Primary. Palatine Tonsil / pathology. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10800174.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] ITALY
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 40
  •  go-up   go-down


25. Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, Hariharan S: Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant; 2003 Oct;17(5):417-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
  • The treatment of PTLD includes reduction/withdrawal of immunosuppression and chemotherapy.
  • This study reports our center experience with humanized monoclonal antibody against CD-20 (Rituximab) for the treatment of PTLD.
  • The mean time between transplant and the diagnosis of PTLD was 57.3 months (range 3 months to 10 yr).
  • RESULTS: The clinical presentation was as follows: lymphadenopathy--5, gastrointestinal bleeding--2 and tonsillar enlargement--1.
  • The diagnosis was made by a lymph node biopsy in five, a gastric ulcer biopsy in two and a tonsillar biopsy in one case.
  • Six of them had polymorphous, two had monoclonal B-cell lymphoma, and all were positive for CD-20.
  • Immunosuppression at the time of PTLD diagnosis consisted of tacrolimus in six cases and cyclosporine A (CsA) in two with mycophenolate mofetil (MMF) and azathioprine--3 each and sirolimus--1.
  • There were no side effects seen with this therapy.
  • One patient who did not respond received chemotherapy.
  • CONCLUSION: Rituximab is an effective agent in the treatment of PTLD without the morbidity characteristic of chemotherapy.
  • Chemotherapy should be reserved only for those refractory to Rituximab therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoproliferative Disorders / drug therapy. Organ Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14703923.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


26. Zeglaoui I, Belcadhi M, Sriha B, Bouzouita K: Nasal NK/T-cell lymphoma in the paediatric population. Two case reports. B-ENT; 2009;5(2):119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal NK/T-cell lymphoma in the paediatric population. Two case reports.
  • Nasal natural killer (NK)/T-cell lymphoma is an uncommon disease, and only a few paediatric cases are found in the literature.
  • We report 2 cases of NK/T-cell lymphoma occurring in children.
  • The primary site was the the nasal cavity in the first case (5-year-old girl) and the tonsil in the second case (4-year-old boy).
  • Both underwent an aggressive chemotherapy regimen.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy. Tonsillar Neoplasms / diagnosis. Tonsillar Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670600.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


27. Mohammadianpanah M, Gramizadeh B, Omidvari Sh, Mosalaei A: Radiation-induced chondrosarcoma of the maxilla 7-year after combined chemoradiation for tonsillar lymphoma. J Postgrad Med; 2004 Jul-Sep;50(3):200-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced chondrosarcoma of the maxilla 7-year after combined chemoradiation for tonsillar lymphoma.
  • Radiation-induced sarcoma is a rare complication of radiation therapy.
  • An 80-year-old Persian woman developed radiation-induced chondrosarcoma of the left maxilla 7 years after combined chemotherapy and external beam radiation therapy for the Ann Arbor stage IE malignant lymphoma of the right tonsil.
  • [MeSH-major] Chondrosarcoma / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / radiotherapy. Maxillary Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Tonsillar Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Time Factors

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15377806.001).
  • [ISSN] 0022-3859
  • [Journal-full-title] Journal of postgraduate medicine
  • [ISO-abbreviation] J Postgrad Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down






Advertisement